Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. APOTEX INC. (D.N.J. 2020)

SUPERNUS PHARMACEUTICALS, INC. v. APOTEX INC. (D.N.J. 2020)

Docket	3:20-cv-07870	Date Filed	2020-06-26
Court	District Court, D. New Jersey	Date Terminated	2023-06-27
Cause	15:1126 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	APOTEX INC.
Patents	10,220,042; 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278
Attorneys	ALEXANDER LEE CALLO
Firms	Saiber, LLC
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. APOTEX INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-26				External link to document
2020-06-26	1	Complaint	9,855,278 (“the ’278 patent”), and United States Patent No. 10,220,042 (“the ’042 patent”), attached hereto…’898 patent, the ’131 patent, the ’600 patent, the ’930 patent, the ’791 patent, the ’975 patent, the…the ’131 patent”), United States Patent No. 8,617,600 (“the ’600 patent”), United States Patent No. 8,821,930…the ’930 patent”), United States Patent No. 9,119,791 (“the ’791 patent”), United States Patent No. 9,351,975…PageID: 2 patent”), United States Patent No. 9,370,525 (“the ’525 patent), United States Patent No. 9,855,278	External link to document

Litigation Summary and Analysis: SUPERNUS PHARMACEUTICALS, INC. v. APOTEX INC. (3:20-cv-07870)

Last updated: February 4, 2026

Case Overview

Supernus Pharmaceuticals, Inc. filed a patent infringement suit against Apotex Inc. in the U.S. District Court for the Northern District of Illinois. The case, docket number 3:20-cv-07870, centers on patent rights related to formulations for treating neurological disorders.

Claim Focus

Supernus owns patents covering formulations and methods of manufacturing specific controlled-release formulations of certain neurological drugs, notably ADHD and epilepsy treatments. The core claim alleges Apotex's generic product infringes on Supernus’s patents by manufacturing a bioequivalent formulation.

Key Patent Allegations

• Patent Numbers: US Patent Nos. 9,206,445 and RE45,690.
• Claim Scope: Patents cover extended-release formulations with specific drug-release characteristics and methods of their manufacturing.
• Patent Validity Issues: Apotex challenges the patents' validity, citing obviousness and lack of novelty.

Procedural Posture

• Complaint filed: October 9, 2020.
• Apotex’s preliminary invalidity contentions: February 2021.
• Markman hearing: April 2021 to interpret claim language.
• Claim construction ruling: July 2021, favoring Supernus in defining key claim terms.
• Summary judgment motions: Filed in late 2021, focusing on patent validity and infringement.

Defenses and Contentions

• Non-infringement: Apotex argues its generic formulation does not infringe due to differences in release profiles.
• Patent invalidity: Due to obviousness, lack of novelty, and written description deficiencies.
• Experimental evidence: Apotex submitted data indicating non-infringement and prior art references.

Key Legal Issues

1. Claim Construction: Interpretation of "extended-release" and "bioavailability" terms, affecting infringement scope.
2. Patent Validity: Whether prior art references render the patents obvious or anticipated.
3. Infringement: Whether Apotex’s generic formulation falls within the scope of Supernus’s patents.

Recent Developments

• December 2022: The court issued an order granting in part and denying in part motions for summary judgment.
• The court found that certain patent claims remained valid but rejected some infringement claims based on the specific formulation differences.
• Trial scheduled for Q2 2023.

Analysis

This case represents a typical patent enforcement action in the pharmaceutical space. It hinges on claim scope, validity, and the interpretation of technical terms in patent claims. The court's claim construction favors precision, requiring detailed understanding of formulation characteristics. Apotex's validity defenses focus on prior art, challenging the patents' novelty and non-obviousness, common in generic drug patent disputes.

Legal precedents in similar patent cases emphasize rigorous claim interpretation and scrutinize validity arguments closely. The outcome may impact the scope of patent protections for extended-release formulations and set a precedent for future disputes concerning patent claims and bioequivalence standards.

Implications for Patent Holders and Generics

• Patent holders need precise claim language and robust validity arguments.
• Generics face challenges in demonstrating non-infringement and invalidity, particularly regarding formulations that mimic patented methods.
• Courts increasingly emphasize detailed claim interpretation and prior art analysis.

Key Takeaways

• Supernus's patent claims cover specific extended-release formulations with defined release characteristics.
• Apotex disputes infringement and validity, citing prior art and formulation differences.
• Claim construction played a pivotal role, affecting infringement scope.
• Summary judgment partly favored Supernus; the trial is ongoing.
• The case underscores the importance of detailed patent drafting and comprehensive validity defenses in pharmaceutical patent disputes.

FAQs

1. How does claim construction influence patent infringement cases?
   Claim construction clarifies the scope of patent claims, determining whether a product infringes. It involves interpreting specific language in patents, affecting legal conclusions on infringement.

2. What are common defenses in patent infringement suits for drugs?
   Typical defenses include non-infringement due to product differences and patent invalidity based on prior art, obviousness, or lack of novelty.

3. How does prior art challenge a pharmaceutical patent?
   Prior art can render a patent invalid if it anticipates the claimed invention or renders it obvious, focusing on chemical formulations, manufacturing processes, or therapeutic methods.

4. What role does summary judgment play in patent disputes?
   Summary judgment can resolve issues of validity or infringement before trial, based on the record showing no genuine dispute of material facts.

5. Will this case affect future generic drug approvals?
   Potentially. If the court finds certain claims invalid or non-infringing, it could influence how generics are designed around existing patents, impacting patent strategies.

Sources

[1] Docket Entry, SUPERNUS PHARMACEUTICALS, INC. v. APOTEX INC., 3:20-cv-07870, Northern District of Illinois.